These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 19770385

  • 1. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
    Leyland-Jones B.
    J Clin Oncol; 2009 Nov 01; 27(31):5278-86. PubMed ID: 19770385
    [Abstract] [Full Text] [Related]

  • 2. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
    Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, Michiara M, Silini EM, Ardizzoni A.
    Cancer; 2011 May 01; 117(9):1837-46. PubMed ID: 21509760
    [Abstract] [Full Text] [Related]

  • 3. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
    Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA.
    Clin Cancer Res; 2011 Jul 15; 17(14):4834-43. PubMed ID: 21768129
    [Abstract] [Full Text] [Related]

  • 4. Central nervous system metastases in breast cancer patients administered trastuzumab.
    Duchnowska R, Szczylik C.
    Cancer Treat Rev; 2005 Jun 15; 31(4):312-8. PubMed ID: 15979804
    [Abstract] [Full Text] [Related]

  • 5. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
    Montagna E, Cancello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M.
    Cancer Chemother Pharmacol; 2009 Jan 15; 63(2):275-80. PubMed ID: 18379783
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E.
    Cancer; 2003 Jun 15; 97(12):2972-7. PubMed ID: 12784331
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.
    Lancet Oncol; 2013 Mar 15; 14(3):244-8. PubMed ID: 23414588
    [Abstract] [Full Text] [Related]

  • 11. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
    Tomasevic ZI, Rakocevic Z, Tomasevic ZM, Milovanovic Z, Inic M, Kolarevic D, Lukic V, Kovac Z.
    J BUON; 2012 Mar 15; 17(2):249-53. PubMed ID: 22740201
    [Abstract] [Full Text] [Related]

  • 12. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
    Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P, Crinò L.
    Oncologist; 2007 Jul 15; 12(7):766-73. PubMed ID: 17673608
    [Abstract] [Full Text] [Related]

  • 13. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M, Trastuzumab Response Biomarker Group.
    Cancer; 2010 Nov 15; 116(22):5168-78. PubMed ID: 20661914
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C, Masuda N, Yoshimura K, Tsuda H, Mano M, Ando M, Tamura K, Fujiwara Y.
    Jpn J Clin Oncol; 2009 Aug 15; 39(8):484-90. PubMed ID: 19477897
    [Abstract] [Full Text] [Related]

  • 20. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge.
    Stemmler HJ, Heinemann V.
    Oncologist; 2008 Jul 15; 13(7):739-50. PubMed ID: 18614587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.